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Vesicles comprised of the ether glycerolipids of the archaeon Methanobrevibacter smithii (archaeosomes) are potent adjuvants
for evoking CD8+ T cell responses. We therefore explored the ability of archaeosomes to overcome immunologic tolerance to self-
antigens.Primingandboostingofmicewitharchaeosome-antigenevokedcomparableCD8+ Tcellresponseandtumorprotection
to an alternate boosting strategy utilizing live bacterial vectors for antigen delivery. Vaccination with melanoma antigenic peptides
TRP181−189 and Gp10025−33 delivered in archaeosomes resulted in IFN-γ producing antigen-speciﬁc CD8+ Tc e l l sw i t hs t r o n g
cytolytic capability and protection against subcutaneous B16 melanoma. Targeting responses against multiple antigens aﬀorded
prolonged median survival against melanoma challenge. Entrapment of multiple peptides within the same vesicle or admixed
formulations were both eﬀective at evoking CD8+ T cells against each antigen. Melanoma-antigen archaeosome formulations also
aﬀorded therapeutic protection against established B16 tumors when combined with depletion of T-regulatory cells. Overall, we
demonstrate that archaeosome adjuvants constitute an eﬀective choice for formulating cancer vaccines.
1.Introduction
Constant immunosurveillance against tumors both in exper-
imental mouse models and cancer patients suggests that
immunotherapy can be an eﬀective way of controlling many
forms of cancer. For example, absence of the cytokine IFN-
gamma or CD8+ T cells and perforin leads to aggressive or
even spontaneous tumor development [1–3]. The identiﬁca-
tion of many T cell-deﬁned tumor antigens over the past two
decades has lead to the logical search for a reliable “widely
applicable” cancer vaccine. Indeed the demonstration in
both mice and humans that T cells of deﬁned antitumor
speciﬁcity can be generated and can eliminate cancers has
been very encouraging [4, 5]. Nevertheless, strategies have
been limiting in their ability to suﬃciently break tolerance
and induce high avidity T cells against cancer self-anti-
gens. Cancer vaccination as opposed to vaccination against
infection poses a unique challenge in that the immune
activation has to occur in the absence of “danger signal”
recognition. Such a response is often weak, does not sustain
for long periods, and leads to tolerance and regulatory T cell
induction [6].
Vaccine adjuvants oﬀer one potential solution to cir-
cumventing the weak response to cancer antigens. The
molecular deﬁnition of danger-associated molecular pat-
terns (DAMPs) has provided a rational choice of immune
modulators such as CpG and other TLR-ligand agonists
[7, 8]. These have been explored as add-ons in vaccine
formulations for boosting cancer vaccine eﬃcacy. Another
approach includes heterologous prime-boost containing
diﬀerent types of vaccine adjuvants that are often able to
increase the breadth and potency of the immune response
[9, 10]. However, the short half-life of small molecule
immunomodulators and potential toxicity of DAMPs often
limit their widespread use. Delivery systems including
liposomes, virus-like particles, microspheres, and ISCOMA-
TRIX adjuvants provide alternative options for formulating
diverse antigenic and adjuvant components and facilitat-
ing speciﬁc immunity with minimal damaging side-eﬀects
[11, 12].2 Clinical and Developmental Immunology
The polar membrane lipids of Archaea are characteristic
of this Domain of life in having isoprenoid chains of
constant length, with novel stereochemistry of ether bond
linkages to sn-2, 3 carbons of the glycerol backbone [13].
We have developed a potent vaccine adjuvant delivery system
constituted by these polar lipids, termed “Archaeosomes”
[11]. Antigen may be entrapped within the hydrophilic core
of the vesicles or anchored in the membrane or linked to
surface-exposed groups akin to antigen-loading principles
for liposomes. Our lead Archaeosome type is composed
of the total natural mixture of polar lipids extracted from
the methanogen, Methanobrevibacter smithii (Ms archaeo-
somes). The superior features of Archaeosomes relative to
conventional liposomes and other adjuvants are recruitment
and activation of dendritic cells in vivo, ability to direct
antigen cargo for MHC class I processing leading to potent
induction of CD8+ T cell response, and stability of archaeal
lipidcoresfacilitatingprofoundimmunememory[14].Most
importantly, these archaeosomes bypass TLR-2- and IL-12-
mediated signaling for activating CD8+ T cells [15].
Thus, we have evaluated the ability of archaeosomes to
eﬀectively break self-tolerance to native melanoma antigens
and aﬀord tumor protection. We show that archaeosomes
can provide strong antitumor immunity to self-antigens and
that a prime-boost strategy with alternate adjuvants was
without beneﬁt.
2.MaterialsandMethods
2.1. Materials. Ovalbumin grade VI, 2-mercaptoethanol,
RBC lysing solution, carboxyﬂuorescein, AEC chromogen
kit, and PKH26 red ﬂuorescent cell linker kit were
from Sigma-Aldrich (Sigma-Aldrich Canada Ltd., Oakville,
Ontario, Canada). Flow cytometry antibodies were pur-
chased from BD Biosciences, RPMI 1640 medium and
gentamicin from Invitrogen Life Technologies, FBS from
HyClone, G418 from Calbiochem, and murine recombinant
IL-2 from ID Labs. Peptides H-2Kb restricted Ova257–264
(SIINFEKL) and HLA.A2/H-2Kb TRP-2180–188 (SVYDF-
FVWL), CTL epitope from tyrosinase-related protein-2 [16],
Gp10025–33 (KVPRNQDWL) from human melanoma anti-
genGp100[17]weresynthesizedin-house.Liverecombinant
Mycobacterium bovis (BCG-OVA) and Listeria monocyto-
genes (LM-OVA) expressing OVA257–264 were constructed as
described previously [18].
2.2. Preparation of Antigen-Loaded Archaeosomes. Peptide-
loaded archaeosome formulations were prepared from the
total polar lipids (TPLs) extract from Methanobrevibacter
smithii (Ms) [19]. GP10025–33 or TRP-2181–189 was entrapped
separately, or a coentrapped preparation was prepared
where both peptides were loaded simultaneously. For model
antigen studies the whole protein Ovalbumin (OVA) was
entrapped in Ms archaeosomes.
A dry lipid ﬁlm containing 20mg TPL was hydrated at
35◦C in 0.5mL of ﬁlter-sterilized Milli-Q water containing
5mg of OVA. In the case of peptides, the hydration was
done in a high pH environment, and the proportion of
the peptide was diminished to avoid aggregate formation
between the charged peptide and the negatively charged
polar lipids. 100mM Triethanolamine (TEA) pH 9 contain-
ing 2mg peptide was added to the dry lipids. Assessment of
archaeosome integrity was done microscopically using phase
contrast at 2000X magniﬁcation. Archaeosomes were bath
sonicated for 1–3min to reduce the vesicles diameter to 100–
200nm and were annealed overnight at 4◦C for membrane
stabilization.
Nonentrapped antigen was removed by ultracentrifuga-
tion at 207,000×g( raverage) for 2h (Beckman centrifuge).
The liposome pellet was washed three times with 8mL of
pyrogen-free ﬁlter-sterilized Milli-Q water. The ﬁnal pellet
was resuspended in 1.0ml of water and ﬁltered through
0.45μm ﬁlters.
2.3. Archaeosome Characterization. Gaussian, number-
weighted size distributions were monitored with a Nicomp
particlesizerModel370,SantaBarbara,CA.Allarchaeosome
vaccines used herein ranged between 80 and 118nm average
diameter. Entrapment eﬃciency was determined based on
the dry weight of a known aliquot and quantiﬁcation of the
incorporated antigen. Ovalbumin content was evaluated
through SDS-PAGE gel electrophoresis and densitometry
of bands revealed by Coomassie blue staining. Peptide
amounts were assayed by RP-HPLC using a Zorbax C-18
reverse-phase column (150×4.6mm) with a guard cartridge
installed in a DX-300 Dionex dual piston HPLC system
(Sunnyvale, CA). The peptides were eluted at a ﬂow rate
of 1mL/min using a gradient aqueous mobile phase from
2% acetonitrile in 0.1% TFA to 70% acetonitrile in 0.085%
T F Ao v e r6 0 m i na n dr e v e a l e db yU Va b s o r b a n c ea ta
216nm wavelength. Integration was done by a Dionex 4290
integrator. Quantiﬁcation was done using a calibration
curve based on known amounts of each of the respective
peptides.
2.4. Mice and Immunizations. Inbred, 6–8-week-old female
C57BL/6J mice were obtained from the Jackson Laboratory
(Bar Harbor, ME) and maintained in the Animal facility
of the Institute for Biological Sciences, NRC, in accordance
with guidelines from the Canadian Council on Animal
Care. Mice were injected subcutaneously (0.1mL volume)
at the base of the tail, with antigen-archaeosomes (Ms-
antigen), antigen in PBS (no adjuvant), or live recombinant
preparations LM-OVA or BCG-OVA as per doses indicated
in ﬁgure legends. All ﬁnal archaeosome preparations were
in PBS prior to the immunizations. Antigen-archaeosome
immunization scheme was based on peptide amounts of 1,
10,15,20,or30μgin0.1mL.Eacharchaeosomeformulation
was named according to the antigen entrapped as Ms-OVA,
Ms-Gp100, and Ms-TRP. Archaeosome preparations with
coentrapped Gp100 and TRP peptides (both peptides within
the same archaeosomes) were named Ms-Gp100-TRP co-
entrap, whereas the ones named Admix were deﬁned by the
combination prior to injection of two (Ms-Gp100+Ms-TRP
admix) of the singly entrapped peptides. For comparison
purposes,theadmixedarchaeosomeimmunizationscenarios
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the coentrapped version. Refer to ﬁgure legends for loading
shown as μg antigen/mg dry weight of the diﬀerent immu-
nization cocktails.
2.5. Cell Lines. EL-4 (H-2b) was obtained from the Amer-
ican Type Culture Collection (ATCC, Rockville, MD) and
maintained in RPMI 1640 medium (Life Technologies,
Grand Island, NY) supplemented with 2-mercaptoethanol,
8% FBS (HyClone, Logan, UT) and 10μg/ml gentamicin
(Life Technologies). B16 melanoma cells were cultured in
RPMI plus 8% FBS. B16OVA cells, expressing the gene
for OVA, were obtained from Dr. Edith Lord (University
of Rochester, NY) and cultured in RPMI plus 8% FBS,
additionally containing 400μg/mL G418.
2.6. Assessment of Numbers of Antigen-Speciﬁc CD8+ TC e l l s
In Vivo. The activation of antigen-speciﬁc CD8+ T cells after
immunization with Ms-OVA, LM-OVA, and BCG-OVA was
tracked in vivo using the tetramer assay. Brieﬂy, peripheral
blood lymphocytes were incubated in 200μL PBS plus 1%
BSA (PBS-BSA) with anti-CD16/32 at 4◦C. After 10min.,
cellswerestainedwithPE-tetramerandanti-CD8for30min.
at room temperature. Cells were washed with PBS, ﬁxed
in 0.5% formaldehyde, and acquired on BD Biosciences
FACS Canto analyzer. The tetramers used include H-
2KbOVA257–264, H-2DbTRP-2180–188, and H-2KbGp10025–33,
all purchased from Beckman Coulter.
2.7. CTL Assays. The antigen-speciﬁc cytolytic activity of
spleen cell eﬀectors after recall stimulation with antigen was
carried out as described in detail previously [20]. Brieﬂy,
spleen cells were cultured with 0.01μg/mL of the appropriate
antigen (TRP2181–189 or Gp10025–33)f o r5d a y sin vitro,
and the ensuing eﬀectors were used in a standard 51Cr-
release CTL assay against nonspeciﬁc and antigen-speciﬁc
targets. EL-4 cells served as the nonspeciﬁc target, whereas
they were preincubated with 10μg/ml of the CTL peptide
for 1h to generate speciﬁc targets. The percent speciﬁc
lysis at various eﬀector:target ratios was calculated using
the formula: [(cpm experimental-cpm spontaneous)/(cpm
total-cpm spontaneous)]×100.
In vivo cytolytic activity of antigen-speciﬁc CD8+ Tc e l l s
was enumerated according to the protocol of Barber et al.
[21]. Donor spleen-cell suspensions from syngeneic mice
were prepared and red blood cells lysed using trisbuﬀered
ammonium chloride (RBC lysing solution). Cells were
stained with the dye PKH26 (4μM) and split into two
aliquots. One aliquot was stained with low concentration
of CFSE (0.5μM) and incubated in R8 medium. The
second aliquot was stained with 10X CFSE (5μM) and
incubated with the appropriate CTL peptide (10μg/mL) in
R8 medium. After 30min. of incubation, the two aliquots
w e r em i x e d1 : 1a n di n j e c t e d( 2 0 ×106/mouse) into pre-
viously immunized recipient mice. PBS-injected recipient
mice served as controls. At 24h after the donor cell transfer,
spleenswereremovedfromrecipients,singlecellsuspensions
prepared, and cells analyzed by ﬂow cytometry. The in vivo
lysis percentage of peptide pulsed targets was enumerated
according to previously published equation [21].
2.8. Enumeration of IFN-γ Secreting Cells. Enumeration of
IFN-γ secreting cells was done by ELISPOT assay. Brieﬂy,
ELISPOT plates were coated with anti-IFN-γ antibody,
blocked, and incubated with spleen cells in various numbers
(in a ﬁnal cell density of 5×105/well using feeder cells)
in the presence of IL-2 (0.1–1ng/mL) and R8 media or
the appropriate CTL epitope peptide (5–25μg/mL) for 48h
at 37◦C, 8% CO2. The plates were then incubated with
the biotinylated secondary antibody (37◦C, 2h) followed
by avidin-peroxidase conjugate (room temperature for 1h).
Spots were revealed using 3-amino-9-ethylcarbazole (AEC
chromogen kit).
2.9. Tumor Model. Mice were injected with 106 B16-OVA or
B16 tumor cells (in PBS plus 0.5% normal mouse serum) in
theshavedlowerdorsalregion.Fromday5onwards,palpable
solid tumors were measured using digital calipers. Tumor
size, expressed in mm2, was obtained by multiplication
of diametrically perpendicular measurements. Mice were
euthanized when the tumor sizes reached a maximum of 300
mm2.
2.10. Statistical Analysis. Unpaired, Student’s t-test was used
to determine the statistical diﬀerence between two groups
of data, whereas one-way ANOVA was used to compare
multiple sets of data. Tumor survival curves were analyzed
by log-rank test. The statistical package of the Graph Prism
software was used for statistical analyses of all data.
3. Results
3.1.PrimingandBoostingwithArchaeosomesConfersSuperior
Quantity of Antigen-Speciﬁc CD8+ T Cell Response. We
have previously shown that Ms archaeosomes prime CD8+
T cell response to entrapped antigen. However, in many
vaccination regimens, particularly for breaking tolerance,
priming and boosting with alternate adjuvants, has been
suggested to increase the magnitude and longevity of
antigen-speciﬁc T cell response. We therefore evaluated
whether boosting with a live vector may improve response
to a primary Ms-OVA injection. Mice that received a single
injection of BCG-OVA or LM-OVA evoked OVA-speciﬁc
CD8+ T cells (based on OVA-tetramer binding) similar in
numbers to those injected with particulate Ms-OVA on
day 7 after immunization (Figure 1(a)). When Ms-OVA
vaccination was followed by LM-OVA injection 30 days later,
a clear increase in the number of antigen-speciﬁc CD8+ T
cells was seen on day 37. However, the magnitude of the
response was similar to priming and boosting with Ms-OVA
(Figures 1(a) and 1(b)). In contrast, a BCG-OVA booster
provided very little enhancement of the antigen-speciﬁc
response primed by Ms-OVA. The in vivo CTL response
to vaccination showed a similar trend (Figure 1(c)), with
single dose vaccines yielding low level of speciﬁc killing,
whereas boosting with Ms-OVA or LM-OVA yielded strong
enhancement of CD8+ T cell cytolytic ability. Therefore,
there was no beneﬁt to using an alternate delivery vector
for boosting.4 Clinical and Developmental Immunology
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Figure 1: CD8+ T cell response after heterologous prime-boost with archaeosomes and live vectors. Mice were vaccinated (subcutaneously)
with Ms-OVA (20μg OVA entrapped in Ms archaeosomes, 94.1nm average size, 38μg/mg loading), or 104 C F Uo fl i v eL M - O V Ao rB C G -
OVA. Prime-boost regimens involved the same Ms-OVA vaccine given on days 0 and 30, or heterologous boost on day 30 with the BCG-OVA
or LM-OVA vector. The CD8+ T cell response was evaluated based on the percentage of OVA257–264 tetramer positive cells in the blood (a, b)
and in vivo CTL response (c). (a) Representative scatter plots showing tetramer positive cells on day 7 after a single injection (top panel) or
after prime-boost on day 37 (bottom panel). The square gate indicates percentage of tetramer positive cells in the blood of immunized mice.
(b, c), Mean±SD of 5 mice per group. ∗Response was statistically signiﬁcant from single dose group by student’s t-test (P<. 05).Clinical and Developmental Immunology 5
3.2. Prime-Boost Vaccination Aﬀords Long-Term Protection
against Melanoma Challenge. We next correlated the CD8+
T cell response evoked by various vaccination regimens
to protection against subcutaneous melanoma challenge.
Mice vaccinated with a single dose of Ms-OVA, LM-OVA,
or BCG-OVA exhibited a median survival of 60, 60, and
31 days, respectively, following subcutaneous melanoma
challenge (Figure 2(a)). In contrast, prime-boost regimens
that involved priming with Ms-OVA followed by boosting
withMs-OVAorLM-OVAaﬀordedsuperiorprotection,with
>90% of vaccinated mice being tumor-free for indeﬁnite
periods. Boosting with BCG-OVA resulted in a median
survival of 45 days, which was greater than a single injec-
tion regimen (Figure 2(b)). Thus, prime-boost vaccination
aﬀordedsuperiortumorprotectiveresponses,butalternating
vector delivery systems had no further beneﬁt.
3.3. Archaeosome Vaccines Break Tolerance to Self-Antigen
Cargo. As priming and boosting with model antigens
entrapped in archaeosomes yielded a strong CD8+ Tc e l l
response and tumor protection, we next evaluated the
response to self-antigen cargo delivered in archaeosomes.
Immunization with 10 to 30μgo fT R P - 2 181–189 peptide
(H-2Kb/HLA A.2 CD8+ T cell epitope) entrapped in
archaeosomes evoked strong peptide-speciﬁc IFN-gamma
productionbyCD8+ TcellsasevaluatedinanELISPOTassay
(Figure 3(a)). This correlated to a strong antigen-speciﬁc
CTL response evoked in immunized mice both in vitro
and in vivo (Figures 3(b) and 3(c)). Above all, immunized
animals showed protection against a melanoma challenge
(Figure 3(d)). Entrapment of Gp10025–33 (H-2Kb/HLA A.2
CD8+ T cell epitope) peptide in archaeosomes also resulted
in IFN-gamma production by CD8+ T cells (Figure 4(a))
and peptide-speciﬁc in vitro and in vivo CTL responses
(Figures 4(b) and 4(c)). Additionally, the CD8+ Tc e l l s
from vaccinated mice exhibited killing of B16 targets (not
pulsed with peptide) in vitro in a standard chromium release
killing assay (Figure 4(b)). It is likely that the weaker killing
response against B16 targets relative to EL-4 peptide target
may be attributable to lower endogenous expression of
MHC-peptides complexes in B16 cells. Importantly, Gp100-
archaeosome vaccination protected mice against subcu-
taneous melanoma challenge (Figure 4(d)). Although the
responses to Gp100 were less dramatic than with TRP-2,
archaeosomes were able in general to evoke functional CD8+
T cell responses to native melanoma antigens.
3.4. Archaeosome-Dual Antigen Formulations Evoke CTL
Responses to Each Individual Antigenic Component. While
archaeosomes could evoke CTL responses to native melan-
oma antigens, the response to the individual antigenic com-
ponent provided vaccinated animals with only a relatively
short-lived protection to tumor challenge. We therefore
coentrapped two melanoma CTL epitopes, TRP-2181–189 and
Gp10025–33 within the same archaeosome vesicles. Follow-
ing vaccination with a coentrapped antigen-archaeosome
formulation, spleen cells of vaccinated mice exhibited CTL
responses speciﬁc to both TRP-2 and Gp100 epitopes
(Figure 5(a)).Nevertheless,theTRP-2-speciﬁcCTLresponse
was weaker than that of Gp100, and this may be attributed
to diﬀerential loading of the two respective peptides in
the coentrapped formulation. A 25μg injection of peptides
corresponded to 20μg Gp100 and 5μg TRP in 1.56mg
archaeosomes. However, vaccination with Ms-TRP and Ms-
Gp100 archaeosomes admixed to achieve the equivalent
20μg Gp100 and 5μg TRP as in the coentrapped formula-
tion, but this time entrapped in only 0.5mg archaeosomes,
resulted in a strong and comparable CTL activity being
evoked against both antigens (Figure 5(b)). Consistent with
the intensity of CTL responses, the coentrapped formulation
aﬀorded a median survival of only 29.5 days to tumor
challenge, whereas immunization with the admixed Ms-
TRP and Ms-Gp100 archaeosomes proved more eﬀective at
providing tumor protection (median survival of 49 days)
(Figure 5(c)). Nevertheless, there was no statistical diﬀerence
between the coentrapped and admixed vaccination group,
and the median survival may be attributable to small sample
size of the study. However, both groups demonstrated statis-
tically signiﬁcant diﬀerence from the control, nonvaccinated
group. Therefore, admixed formulations simply provide a
convenient means of controlling a more optimized dose and
loading.
3.5. Targeting Dual Melanoma Antigens with an Admixed
Archaeosome Formulation Aﬀords Long-Term Tumor Protec-
tion. In the above experiments, the admixed formulation of
archaeosomes contained suboptimal amounts of melanoma
antigens in order to serve as appropriate comparison to the
coentrapped formulation. In order to test the full potential
of targeting multiple melanoma antigens with archaeosome
adjuvants, vaccination was carried out with a mixture of
archaeosomemelanomapeptideformulationssuchthateach
antigen was provided in an equivalent dose of 30μg, on day
0 and 21. Firstly, IFN-gamma production by CD8+ Tc e l l s ,a s
evaluated in an ELISPOT assay on day 28 after vaccination,
indicated a response against both TRP-2 and Gp100 peptide
stimulations using the admixed formulation (Figure 6(a)
and 6(b)). However, the antigen-speciﬁc response to Gp100
peptide was weaker when administered in an admixed for-
mulation relative to Gp100-archaeosome by itself. Antigen-
speciﬁc tetramer was also detectable in the blood on day 28
after priming against both peptides with the admixed for-
mulation(Figure 6(c)).Hereagain,theendogenousresponse
to Ms-Gp100 vaccine was stronger when administered
by itself than in an admixed formulation. The CD8+ T
cells evoked after admixed immunization eﬀectively killed
targets expressing TRP or Gp100 (Figure 6(d)), although
the killing against TRP-expressing targets was stronger than
the killing against Gp100 targets. Overall it appears that
when coadministered, the TRP epitope may dominate in
response over Gp100. Finally, we addressed the ability of the
admixed vaccine to evoke tumor protection. In all previous
experiments, tumor challenge was conducted at 6 weeks pos-
timmunization, possibly during the declining phase of the
T cell response. Therefore, we compared protection against
tumors given at either 4 or 6 weeks postvaccination. Ms-
Admixed formulation aﬀorded signiﬁcant protection (P<
.01) when tumor challenge was carried out at either 4 or 66 Clinical and Developmental Immunology
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Figure 2: Tumor protection following heterologous prime-boost vaccination. C57BL/6J mice were vaccinated subcutaneously with a single
dose of Ms-OVA (20μgO V A ,3 8μg/mg lipid loading, 94.1nm average archaeosome size), LM-OVA (104 CFU), or BCG-OVA (104 CFU) or
withaprime-boostregimenasindicated.MicewerechallengedwithsubcutaneousB16-OVAtumors4weekspostvaccination.Survivalplots
are based on euthanizing animals upon reaching a maximum tumor size of 300mm2 (n = 5/group). Survival curves for vaccinated groups
were signiﬁcantly diﬀerent from na¨ ıve group by log-rank test (∗∗P<. 01, ∗∗∗P<. 001).
weeks postvaccination (Figure 6(e)). Furthermore, there was
no statistically signiﬁcant diﬀerence in the protection seen
at early (4 week) versus late (6 weeks) postvaccination (P =
.4) suggesting ability of archaeosomes to aﬀord memory
responses to self-antigens. Comparing the aggregate data
from several experiments, the median survival for TRP-2-
orGp100-archaeosomessingle-peptidevaccineadministered
p r e v e n t a t i v e l yw a s2 2d a y sr e l a t i v et o<17 days for na¨ ıve
nonvaccinated mice. In contrast, targeting responses to
both peptides using an admixed vaccine markedly improved
median survival to 35 days.
3.6. Therapeutic Protection against Established B16 Tumors
by Peptide-Archaeosome Vaccine. Induction of prophylactic
protection against cancer vaccines is often relatively easy to
achieve, whereas breaking tolerance against an established
tumor in a therapeutic setting can be challenging. Indeed,
the admixed formulation of TRP- and Gp100-archaeosomes
aﬀorded only marginal protection (median survival of 24
days relative to median survival of 20 days for nonvaccinated
group) when administered therapeutically following tumor
challenge (Figure 7). However, when combined with prior
depletion of T-regulatory cells using anti-CD25 antibody a
signiﬁcant decrease (P<. 01) in tumor size (Figure 7(a))
and increased median survival (P<. 01) were observed
(Figure 7(b)). Thus, archaeosome vaccines appear to hold
promise for tumor vaccination when combined with other
vaccination strategies that target tumor evasion.
4. Discussion
Archaeosomes are eﬀective self-adjuvanting delivery systems
that target processing of antigenic cargo for MHC class
I presentation leading to potent long-term CD8+ Tc e l l
responses. In previous studies using model antigens we
demonstrated that following immunization of mice with
Ovalbumin(OVA)-Archaeosomes, ∼3.5%ofallCD8+ Tc ells
in the spleen were OVA-speciﬁc by day 7, and boosting
on day 21 resulted in expansion to ∼20% on day 28 [14].
Furthermore, a prolonged memory response ensued that
was complemented with a strong functional cytolytic ability
of CD8+ T cells and protection against OVA-expressing
tumors in prophylactic and therapeutic settings [15]. Thus,
we pursued the ability of archaeosomes to evoke adaptive
immune responses to entrapped tumor-associated antigens.
The generation of high frequencies of functional antigen-
speciﬁc CD8+ T cells against two tumor-associated antigens,
as assessed by IFN-γ secretion, enumeration of tetramer-
binding antigen-speciﬁc CD8+ T cells, and in vitro and
in vivo cytotoxic assays prove archaeosomes as a highly
eﬀective adjuvant for breaking tolerance to tumor self-
antigens.
Microparticulate carrier systems such as archaeosomes
preferentially accumulate in APCs and thus can eﬀectively
target antigens for presentation onto MHC class I. However,
secondary costimulatory signals are required for breaking
tolerance to self-antigens which are often lacking in the
contextoftumorsduetolackofdanger-associatedmolecular
patterns. Advantageously, archaeosomes exhibit the unique
ability to induce dendritic cell maturation and increase
costimulation [22]. Furthermore, archaeosomes evoke CD8+
T cell response in an IL-12-independent manner [15].
Thus, archaeosome vesicles uniquely bring together many
beneﬁcial features for tumor antigen presentation: antigen
targeting to APC and costimulation in the absence of overt
inﬂammationleadingtoeﬀectiveadaptiveimmunityinasafe
manner.Clinical and Developmental Immunology 7
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Priming and boosting of an immune response has been
traditionally recognized as an eﬃcient way of maintaining
long-term immunity. Indeed most vaccines against infec-
tious diseases are often given multiple times and since
priming and boosting occurs with the same vaccine, they
are considered homologous prime-boost regimens. Het-
erologous prime-boosting with unmatched vaccine delivery
systems or adjuvants but the same antigen was ﬁrst reported8 Clinical and Developmental Immunology
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in the early 1990s to be an eﬀective strategy for evoking a
balanced humoral and cell-mediated immunity [23]. Early
studies focused on live viral vectors expressing antigens
followed by a protein or peptide boost. With the advent
of DNA vaccines that were weakly immunogenic, once
again priming with DNA vaccine followed by boosting
with a protein and peptide antigen proved to be eﬀec-
tive strategy [24]. Since then, prime-boost regimens have
been evaluated for several new generation vaccines against
HIV, malaria, and tuberculosis. Heterologous prime-boost
approaches can improve vaccine immunity by inﬂuencing
the immunogenicity of antigens, allowing dose sparing,
diversifying the quality of immunity, and circumventing
the negative eﬀects of neutralizing antibodies against the
priming vector [9, 10, 24–26]. A heterologous prime-
boost protocol involving diﬀerent viral vectors expressingClinical and Developmental Immunology 9
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the same melanoma-polypeptide induced 100 times greater
frequencies of vaccine-induced CD8+ T cells [27]. We thus
rationalizedthatifaheterologousprime-boostregimesusing
model antigen-archaeosome vaccines were beneﬁcial, this
approach may be beneﬁcial for cancer antigen delivery using
archaeosomes. Our results indicate that while priming and
boosting (2 injections) aﬀorded superior tumor protection
relative to a single injection regimen, there was no beneﬁt to
boosting with an alternative delivery system. The ineﬃciency
of BCG-OVA to boost a good immune response may be
related to its slow growth and low antigen expression. In
contrast, 2 injections of Ms-OVA archaeosomes aﬀorded
superiortumorimmunitycomparableineﬃcacytoboosting
with LM-OVA. Archaeosomes comprised of polar lipids of
M. smithii do not usually evoke antilipid responses and
hence demonstrate an advantage to be repeatedly utilized in
vaccination regimens.
Useoftumorantigenicpeptidesprovidesaquick,simple,
and inexpensive manner of targeting induction of antitumor
responses. T cell immunity against multiple antigenic deter-
minants may be evoked. Peptides can be easily formulated
to be tested in various settings, including altered peptide10 Clinical and Developmental Immunology
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ligands, lipidated peptides, combination with heterologous
helper peptides, and comparison of various adjuvants. Over
the past decade, CTL epitopes of several melanoma antigens
have been identiﬁed, and epitopes of melanoma antigens
Gp100 and TRP-2 are widely targeted in clinical trials [4, 28–
32]. Thus, we chose the use of these peptides for proof-of-
concept studies to demonstrate the ability of archaeosomes
to overcome self-tolerance. The overall negative charge
of the total polar lipids mixture from Methanobrevibacter
smithii with its high phospholipids content together with
the charge/solubility of the peptides being used is major
factors to consider during vaccine formulation. Each peptide
type was solubilized and made into an appropriate overall
charge and which had to be compatible with the hydration
of the dry lipid ﬁlm required for archaeosome formation.
GP100 and OVA peptides were all more or less hydrophilic
in character, whereas TRP-2 was more hydrophobic and
required the addition of some propanol. TRP-2 peptideClinical and Developmental Immunology 11
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is acidic whereas GP100 peptide is basic. To avoid the
aggregation of archaeosomes, a basic pH environment was
favoured, and the lipid-peptide ratio was kept around 10:1
w/w. In this study, results are showing equivalent immune
response using the admixed approach. The formulation of
multiple peptide-archaeosome by admixing is appealing,
since it requires optimization for only a single peptide at
a time and may facilitate consistency of formulation and
reproducibility.
Vaccination with two melanoma antigen-archaeosomes
aﬀorded superior tumor protection in comparison to sin-
gle antigen-archaeosome vaccines indicating that targeting
responses to multiple antigens is an eﬃcient way of break-
ing tolerance. Moreover coentrapment and/or admixture
of individual peptide encapsulated archaeosomes aﬀorded
tumor protection. As archaeosomes are eﬃciently phago-
cytosed by antigen presenting cells (APC), coentrapped
antigens within the same vesicle may be targeted for
release within the same APC. Once released in the intra-
cellular milieu, peptides may compete for binding to the
transporter associated with antigen processing (TAP), and
diﬀerential binding of melanoma peptides to TAP has been
reported [33, 34]. The diﬀerential CTL response to the
two peptides following coentrapment may be reﬂective
of their diﬀerential binding to TAP or just diﬀerence
in the amount of each peptide that was coentrapped.
Moreover, peptides may also compete for binding to the
same MHC molecules, and epitopes with higher avidity for
the MHC-I complex may outwit weakly binding peptides.
In contrast, when peptides are individually entrapped and
used in an admixed formulation, each antigen is targeted
individually for presentation by the APC. Furthermore,
optimized amounts of each antigen may be included in
the vaccine. Our results demonstrate that admixed peptide-
archaeosome formulations induced CTL responses against
both epitopes. It has been previously shown that recognition
of melanoma CTL epitopes with diﬀerent aﬃnities can
be achieved following multiple peptide formulation [35].
Nevertheless, even with the admixed vaccine, responses to
t h eT R P - 2p e p t i d ew a ss t r o n g e rb a s e do nf r e q u e n c yo f
IFN-gamma secreting cells, tetramer+ CD8+ Tc e l ln u m b e r ,
and CTL response. Indeed, it has been suggested that
with multiple peptide vaccinations, competition between
CTLs can narrow the repertoire of the immune response
evoked [27]. Despite such a possibility, multiple peptide
immunization often provides a cumulatively stronger over-
all CD8+ CTL response [36]. Indeed, the dual-peptide
archaeosome vaccine aﬀorded longer-term tumor protec-
tion relative to the single-peptide archaeosome formula-
tion.12 Clinical and Developmental Immunology
A number of particulate delivery systems have been eval-
uated for cancer vaccine delivery. Conventional liposomes
carrying cytokines such as IL-2 and IFN-gamma were tested
for their eﬃcacy to deliver cancer antigens but showed
limited promise in breaking tolerance [37, 38]. Cationic
liposomesposedtheeaseforeﬃcientassociationwithdiverse
negatively charged antigens including DNA [39] but their
high positive charge and large size lead to quick clearance
from the blood and to tissue toxicity. More recently, lipid
particle-based nanovesicles with neutral charge were utilized
to deliver negatively charged CpG oligonucleotides in a
safe and consistent manner [40]. A novel proteoliposomal
vaccine prepared from the cell membrane proteins of
lymphoma cells was also shown to be more eﬃcient in
inducing antitumor responses than conventional liposomes
[41]. ISCOM vaccines that combine TLR9 agonists have
been reported to break tolerance in an orthotopic model of
pancreatic carcinoma [42].
In many cases combination immunotherapy includes
novel vaccination regimens to overcome immunologic tol-
erance. A synthetic TRP2180–188 peptide vaccine was recently
combinedwithseveraltoll-likereceptoragonistsandananti-
CD40antibodytoinducepotentCD8+ Tcellswiththerapeu-
tic tumor eﬃcacy against established B16 melanoma [43].
Other strategies to counteract tumor evasion and promote
long-term tumor recession have included blocking T regu-
latory cells and programmed death-ligand interactions, or
co-use of adoptive T cell transfer [44, 45]. We also observed
that while both Gp100- and TRP-2-archaeosome vaccines
evoked antigen-speciﬁc CD8+ T cell response indicating
their ability to break tolerance, tumor protection against
established tumors required depletion of T regulatory cells.
Indeed, it is now well established that T regulatory cells
can hinder the protective eﬃcacy of tumor-speciﬁc CD8+
T cells. An anti-CD25 monoclonal antibody, daclizumab,
has been eﬀectively trialed for the depletion of T-regulatory
cells and improved eﬃcacy of a coadministered peptide-
vaccine against human breast cancer [46]. Our studies
reiterate that induction of functional CD8+ T cells alone
is an insuﬃcient marker for predicting tumor protection
and immunotherapy may require additional strategies to
counteract tumor evasion. Thus, archaeosomes should be
further evaluated as a promising adjuvant delivery system for
immunotherapeutic vaccination regimens.
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